Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Rocket Pharmaceuticals, Inc. Common Stock

RCKT

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.

Last trade $2.11
Day change -$0.055 (-2.55%)
Day range $2.04 – $2.24
Volume 1,266,177
Market cap $241M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$241.19M
Price / earnings
—
Price / book
0.74×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.07×

Profitability

Earnings per share
-$0.14
Return on assets
-3.85%
Return on equity
-4.94%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.16×
Current ratio
7.26×
Quick ratio
7.25×
Cash ratio
2.49×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$159.23M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for RCKT, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$19.79M$17.43M$17.06M$14.68M$18.35M$25.02M$28.45M$25.34M
Research and development$31.17M$29.5M$31.45M$29.35M$34.07M$42.66M$35.94M$37.36M
Total operating expenses$50.97M$46.92M$48.51M$43.96M$52.25M$71.15M$64.39M$62.69M
Operating income-$50.97M-$46.92M-$48.51M-$43.96M-$52.25M-$71.15M-$64.39M-$62.69M
Interest expense-$473K-$473K-$473K-$473K-$473K-$473K-$472K-$473K
Income before taxes-$49.18M$131.84M-$48.82M-$42.54M-$50.33M-$68.92M-$63.52M-$60.33M
Income taxes$54K$8.62M$0$0$0$0$0$0
Net income-$49.23M$123.21M-$48.82M-$42.54M-$50.33M-$68.92M-$63.52M-$60.33M
Net income attributable to common shareholders-$49.23M$123.21M-$47.59M-$42.54M-$50.33M-$68.92M-$61.33M-$60.33M
EBITDA-$49.47M-$45.36M-$46.9M-$42.35M-$49.72M-$65.64M-$61.94M-$60.87M
Basic earnings per share-$0.43$1.09-$0.42-$0.38-$0.45-$0.62-$0.56-$0.62
Diluted earnings per share-$0.43$1.08-$0.42-$0.38-$0.45-$0.62-$0.56-$0.62

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

RCKT DEADLINE TOMORROW: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Rocket Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 11 Deadline in Securities Class Action – RCKT

Rosen Law Firm alerts Rocket Pharmaceuticals investors about a securities class action lawsuit alleging false statements regarding the effectiveness and safety of drug candidate RP-A501, with an important deadline on August 11, 2025.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.